- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on BioMarin Pharmaceutical Inc. (BMRN)
by latest | most commented
-
Passport Capital Chooses Gold over Education
-
Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly
-
Monday Options Recap
-
Monday Options Update: NVAX, BMRN, TIVO & OI
-
Does More Cash and Less Debt Equal Stock Market Gains?
-
Biotech M&A Action: We've Only Just Begun
-
Where Might Genentech Investors Redeploy $47B?
-
Big Mergers Could Mean Sweet Gains for Biotech
-
La Jolla Drug Failure Leaves Few Options
-
Bullish Thesis for Biotech Remains Intact
-
Looking for the Biotech Breakout
-
SAC Capital Portfolio Update: 37 13G Filings
-
Hedge Fund Portfolio Tracking: Citadel Investment Group (Ken Griffin), Q3 2008
-
BioMarin Rolls the Dice on a New Lupus Drug
-
New Emerging Biotech and Pharma Company Index
-
Four Biotechs at Attractive Entry Points
-
Even Fatter Yields for Pfizer; M&A Targets in the Sector
-
Friday Options Update: MS, XLF, GFG, MTB, XLB, BMRN, IWM
-
Biotech Outlook: M&A Will Continue
-
Biotech Buying Binge About to Begin?
-
Big Biotech Booms But IBB Falls Flat
-
BioMarin, Myriad, and Regeneron Show a Quiet Strength
-
Biotech Sector Continues to Outperform
-
Five Biotech Stocks to Weather a Down Market
-
Smallcap BioMarin's Drug Kuvan Showing Great Promise
-
Gold's Just Getting Started - Barron's Interview
-
Biotech Fund IBB May Ride the M&A Frenzy, but It's Still Wildly Volatile
-
Look Who's Buying Shares of BioMarin Pharmaceutical
-
Biotech Day in Review: Shire Buys New River for $2.6 Billion
-
Biotech Stocks Day-in-Review: BioCryst Begins Pivotal Trial of Fodosine
-
Biotech Stocks Day-in-Review: Controversy For Genentech Cancer Drug
-
BioMarin Recieves Approval for Aldurazyme in Japan
-
Chart: Biotech Stocks - Annual Earnings Growth
-
Chart: Biotech Stocks - Quarterly Earnings Growth
-
Analyst Upgrades & Downgrades for Wednesday, July 19, 2006
-
Chart: Biotech Stocks - Annual Revenue Growth (Last 12 Months Reported)
-
Chart: Biotech Stocks - Quarterly Revenue Growth
-
Chart: Biotech Stocks - Change in Cash-On-Hand
-
Chart: Biotech Stocks - Normalized Net Income Per Employee
-
Chart: Biotech Stocks - Revenue Per Employee
-
Chart: Biotech Stocks - Normalized Net Profit Margins